chlorin e6

Chlorin E6 (CE6) is a second-generation photosensitizer with antitumor activity when used in combination with irradiation. In a mouse model of implanted fibrosarcoma, Chlorin E6 (2.5-10 mg/kg, i.v., 50-200 J/cm2 irradiation) resulted in complete tumor disappearance after varying degrees of irradiation. Agents including Chlorin E6 were tested in a Phase I clinical study in patients with early superficial squamous cell carcinoma of bronchial origin with favorable results (40 mg/m2, IV, 100 J/cm2 laser irradiation). In a Phase II clinical trial in patients with early stage lung cancer, the same mode of administration resulted in a complete response in 82.9% of patients. Chlorin E6 has been investigated as a nanotechnology drug delivery tool.

Chlorin e6 trimethyl ester is a porphyrin compound derived from chlorophyll. Its carboxyl group is methylated to enhance its fat solubility, and it is commonly used as a photosensitizer in photodynamic therapy (PDT) and fluorescence imaging studies. When exposed to light of a specific wavelength, chlorin e6 trimethyl ester generates reactive oxygen species (such as singlet oxygen), thereby inducing oxidative damage and cell death.

Talaporfin is a photosensitizer used in photodynamic therapy.

LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).

RCK00826, also known as Monotyrosine amide of chlorin e6 trisodium salt, is a naturally derived porphyrin compound.